Latest News and Press Releases
Want to stay updated on the latest news?
-
White Oak, Md., April 24, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV)...
-
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
-
Franklin, Tennessee, April 23, 2026 (GLOBE NEWSWIRE) -- The ROOT Brands, a patent‑driven consumer wellness company built on science‑backed innovation and cellular health research, announced today...
-
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid...
-
Oxford Treatment Center sounds warning this Alcohol Awareness Month, citing rise in patients seeking alcohol addiction treatment.
-
Chicago, IL, April 23, 2026 (GLOBE NEWSWIRE) -- On April 23, Cook County Health proudly celebrated the 60th anniversary of the Trauma & Burn Department at John H. Stroger, Jr. Hospital, honoring...
-
AI-driven monitoring is increasingly used to improve precision, efficiency, and safety in spine, neurosurgical, and ENT procedures.
-
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company...
-
PridCor secures global antiviral portfolio with Phase 2b and Phase 3 assets to advance treatments for Long COVID and chronic illness.
-
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients...